Physicians' Academy for Cardiovascular Education

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, United Kingdom - Online CME

Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.

Video navigation menu

  • PCSK9: mechanism of action and CHD risk reduction 01:30
  • Mendelian randomization PCSK9 and statin trials 03:24
  • Comparison of statin CTT and PCSK9 inhibitor trials 06:29
  • PCSK9 inhibitors and statins compared by duration of treatment 07:59
  • Statins and PCSK9 inhibitors: Effect size by year of treatment 08:48

Educational information

This lecture by prof. Brian Ference was part of a CME accredited symposium: "PCSK9 inhibition: Science, outcomes and guidance" held at ESC 2018 in Munich, Germany.


Prof. Brian Ference, MD - Cambridge, UK


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Amgen and Sanofi-Regeneron.

View slides of prof. Ference


This is available as accredited online CME on coursepath for members. Click the button below to enroll:

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: